Abstract
Objective
To determine if epigenetic-modifying drugs can increase iodine uptake in thyroid carcinoma cell lines.
Study Design
Human thyroid carcinoma cell lines were tested for iodine uptake before and after treatment with epigenetic-modifying agents.
Results
Thyroid carcinoma cell lines DRO and 2–7 had high levels of DNA methylation (74% and 80%) compared with normal thyroid tissue (6%) (P < 0.05). This finding correlated with low levels of sodium iodide symporter (NIS) expression in the untreated thyroid carcinoma cell line. Combination treatment with the epigenetic-modifying agents 5-aza-2'-deoxycytidine and sodium butyrate resulted in increases in NIS messenger RNA levels, global histone acetylation, and 9- and 8-fold increases in I125 uptake for the DRO and 2–7 cells, respectively.
Conclusions
Epigenetic-modifier drugs represent a novel adjuvant treatment for those patients with radioablation-resistant thyroid cancer.
Significance
Epigenetic-modifying agents show potential for treatment of radioablation-resistant thyroid cancer.
Get full access to this article
View all access options for this article.